What amount sold does ACELRX PHARMACEUTICALS INC report in Form D filings?

The latest linked filings report $97.4M sold across 10 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was ACELRX PHARMACEUTICALS INC's most recent SEC filing?

ACELRX PHARMACEUTICALS INC's most recent Form D filing was on 2025-09-15.

How many investors does ACELRX PHARMACEUTICALS INC have?

The most recent Form D filing lists 13 investor(s).

What type of securities does ACELRX PHARMACEUTICALS INC offer?

ACELRX PHARMACEUTICALS INC's SEC Form D filings indicate equity offerings.

ACELRX PHARMACEUTICALS INC

CIK: 0001427925·Pharmaceuticals·SAN MATEO, CA·Corporation

Reported Sold

$97,350,864

Total Filings

Identified Offerings

Last Filed

Sep 15, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Sep 15, 2025Form D — New notice

Reported sold: $16,984,999 · Target: $28,969,997

Rule 506(b)·13 investors

Apr 17, 2025Form D — New notice

Reported sold: $4,920,000 · Target: $15,000,000

Rule 506(b)·11 investors

Jan 29, 2024Form D — New notice

Reported sold: $6,000,000 · Target: $6,000,000

Rule 506(b)·6 investors

Jul 28, 2023Form D — New notice

Reported sold: $10,000,008 · Target: $10,000,008

Rule 506(b)·10 investors

Aug 17, 2022Form D — New notice

Reported sold: $629,958 · Target: $629,958

Rule 506(b)·1 investor

Jan 24, 2022Form D — New notice

Reported sold: $5,160,997 · Target: $5,960,979

Rule 506(b)·32 investors

Jun 7, 2012Form D — New notice

Reported sold: $10,000,002 · Target: $10,000,002

Rule 506·10 investors

Jul 13, 2011Form D — New notice

Reported sold: $20,839,994 · Target: $20,839,994

Rule 506·2 investors

Sep 21, 2010Form D — New notice

Reported sold: $8,000,800 · Target: $12,001,200

Rule 506·8 investors

Nov 25, 2009Form D — New notice

Reported sold: $14,814,106 · Target: $30,000,000

Rule 506·8 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$1,675,001

Amendment Rate

Latest reported sold across 10 identified offerings

$97,350,864

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Mark Wan

Related Person

Appears on 3 filings

Raffi Asadorian

Related Person

Appears on 3 filings

Adrian Adams

Related Person

Appears on 3 filings

Vincent J Angotti

Related Person

Appears on 3 filings

Jill Broadfoot

Related Person

Appears on 3 filings

Marina Bozilenko

Related Person

Appears on 3 filings

Stephen J Hoffman

Related Person

Appears on 3 filings

Abhinav Jain

Related Person

Appears on 3 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Sep 15, 2025	New	$28,969,997	$16,984,999	13
Apr 17, 2025	New	$15,000,000	$4,920,000	11
Jan 29, 2024	New	$6,000,000	$6,000,000	6
Jul 28, 2023	New	$10,000,008	$10,000,008	10
Aug 17, 2022	New	$629,958	$629,958	1
Jan 24, 2022	New	$5,960,979	$5,160,997	32
Jun 7, 2012	New	$10,000,002	$10,000,002	10
Jul 13, 2011	New	$20,839,994	$20,839,994	2
Sep 21, 2010	New	$12,001,200	$8,000,800	8
Nov 25, 2009	New	$30,000,000	$14,814,106	8

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

CeleCor Therapeutics, Inc.

Pharmaceuticals

Offering target: $15,000,000

Filed Jul 9, 2026